March 3, 2026Open Access

Dual Specificity Phosphatase (DUSP22) promoter hypomethylation in cell-free DNA is associated with rheumatoid arthritis and its radiographic severity

Key Points

DUSP22 cfDNA methylation may serve as a promising biomarker for evaluating rheumatoid arthritis severity,
Findings indicate an association with clinical characteristics; larger studies are needed for validation.
Exploratory pilot study assessed cfDNA methylation regarding rheumatoid arthritis in diverse patients.
Moreover, DUSP22 hypomethylation could enhance non-invasive diagnostics in rheumatology.

Abstract

Our pilot study is the first to evaluate cfDNA methylation association to RA clinical characteristics. These exploratory findings suggest that DUSP22 cfDNA methylation may represent a promising non-invasive biomarker in rheumatoid arthritis, a hypothesis that warrants validation in larger and ethnically diverse populations.

Dual Specificity Phosphatase (DUSP22) promoter hypomethylation in cell-free DNA is associated with rheumatoid arthritis and its radiographic severity

Key Points

Abstract

Cite This Study

Also Consider

Also Consider